본문 바로가기

Meet Us at European Society of Gene & Cell Therapy (ESGCT) 2024 Congress

Meet Us at EORTC-NCI-AACR (ENA) 2024 Symposium

Meet Us at European Society of Gene & Cell Therapy (ESGCT) 2024 Congress.

mRNA-based cancer vaccine simultaneously targeting multiple KRAS mutations induces robust anti-tumor immune responses in various KRAS mutant cancers
Poster Number
P0916
Session
Poster session IV Non viral vectors/Nanotechnology/RNA therapeutics, Oct 24 at 18:00 PM ~ 19:30 PM GMT+2, Concourse Level-1 and Mezzanine Concourse
Presenter
Yong Ho Heo, Ph.D.
/ Hanmi Pharmaceutical

yhheo79@hanmi.co.kr

Harnessing mRNA-based therapy to restore p53 function to suppress growth of p53 mutant cancers
Poster Number
P0922
Session
Poster session IV Non viral vectors/Nanotechnology/RNA therapeutics, Oct 24 at 18:00 PM ~ 19:30 PM GMT+2, Concourse Level-1 and Mezzanine Concourse
Presenter
Youngjin Han, Ph.D.
/ Hanmi Pharmaceutical

youngjin.han@hanmi.co.kr

Meet Us at EORTC-NCI-AACR (ENA) 2024 Symposium.

A novel and potent MAT2A inhibitor, HM100760, demonstrates anti-tumor activity in MTAP-deleted cancers
Poster Number
PB057
Session
Molecular Targeted Agents (Poster), Oct 23 at 12:00 PM ~ 19:00 PM CEST, Exhibition Hall
Presenter
Eun Joo Kwak /
Hanmi Pharmaceutical

keunj83@hanmi.co.kr

HM99462, a novel SOS1 inhibitor, induces tumor regression and synergistic effect with KRAS or EGFR targeted therapy in NSCLC
Poster Number
PB070
Session
Molecular Targeted Agents (Poster), Oct 23 at 12:00 PM ~ 19:00 PM CEST, Exhibition Hall
Presenter
Wongi Park /
Hanmi Pharmaceutical

wongi.park@hanmi.co.kr

Discovery of potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitors targeting HER2 exon20 insertion mutants and HER2WT
Poster Number
PB094
Session
Molecular Targeted Agents (Poster), Oct 23 at 12:00 PM ~ 19:00 PM CEST, Exhibition Hall
Presenter
Hyung-Seok Yoo, Ph.D. / Hanmi Pharmaceutical

hyungseok.yoo@hanmi.co.kr

Hanmi's New Story

힘차게 도약하는 한미
함께하는 미래

한미약품의 새로운 이야기가 펼쳐집니다.

The Hanmi Way

No path started as a path.
We seek a better future for humanity on it.

View More
main3 main3

Innovation

Korea's leading R&D-centric healthcare company.
We create never-before-seen innovation through bold challenges.

asdfa asdf

Respect, Trust, Integrity

We lead the global healthcare industry
through Respect, Trust, and Integrity.

Focus on Making
Innovative Medicines

한미약품은 다양한 치료 영역을 포괄하는
탄탄한 R&D 인프라를 바탕으로
제약분야에서 혁신을 선도하고 있습니다.

비만/대사

비만, 대사 이상 관련 지방간염 등 다양한 작용기전
Best-in-class 신약 개발

View More

What We Make

ESG Report

한미약품의 ESG 경영은
'일상의 혁신'입니다.

View More

당신의 꿈이
한미약품의 미래입니다.
당신을 기다립니다.

Join Us